HOUSE BILL 1502
J1 5lr3585
CF 5lr3586
By: Delegate Wells (By Request – Baltimore City Administration)
Introduced and read first time: February 14, 2025
Assigned to: Rules and Executive Nominations
Re–referred to: Health and Government Operations, February 25, 2025
Committee Report: Favorable
House action: Adopted
Read second time: March 6, 2025
CHAPTER ______
1 AN ACT concerning
2 Baltimore City – AIDS Prevention Sterile Needle and Syringe Exchange Pilot
3 Program – Revisions
4 FOR the purpose of renaming the AIDS Prevention Sterile Needle and Syringe Exchange
5 Pilot Program to be the HIV Prevention Syringe Services Program; altering the
6 duties of the Program, the Director of the Program, and the Baltimore City Health
7 Department regarding the Program; altering the membership and duties of the
8 Program’s oversight committee; altering the immunity provided to Program staff and
9 participants; and generally relating to the AIDS Prevention Sterile Needle and
10 Syringe Exchange Pilot Program.
11 BY repealing and reenacting, without amendments,
12 Article – Health – General
13 Section 24–801(a)
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Health – General
18 Section 24–801(e), 24–802 through 24–806, 24–808, and 24–809
19 Annotated Code of Maryland
20 (2023 Replacement Volume and 2024 Supplement)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb1502*

2 HOUSE BILL 1502
1 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
2 That the Laws of Maryland read as follows:
3 Article – Health – General
4 24–801.
5 (a) In this subtitle the following words have the meanings indicated.
6 (e) “Program” means the [AIDS] HIV Prevention [Sterile Needle and] Syringe
7 [Exchange Pilot] SERVICES Program.
8 24–802.
9 (a) There is an [AIDS] HIV Prevention [Sterile Needle and] Syringe [Exchange
10 Pilot] SERVICES Program in the Baltimore City Health Department.
11 (b) The Program shall:
12 (1) [Provide] DISTRIBUTE SYRINGES AND PROVIDE for the exchange by
13 participants of used hypodermic needles and syringes for sterile hypodermic needles and
14 syringes AS NEEDED; and
15 (2) Operate in accordance with the procedures approved, with the advice
16 and approval of the oversight committee, by the Commissioner of Health.
17 24–803.
18 The Program shall:
19 (1) Be designed and maintained to provide [maximum security of exchange
20 locations and equipment, including] security measures [that may be] AND PROCESSES
21 required to [control the use and dispersal of] SAFELY DISTRIBUTE hypodermic needles
22 and syringes and [security measures that allow for a full accounting of] ACCOUNT FOR the
23 number of hypodermic needles and syringes [in circulation] EXCHANGED AND
24 DISTRIBUTED BY THE BALTIMORE CITY HEALTH DEPARTMENT and the number of
25 hypodermic needles and syringes in storage;
26 (2) Be operated to allow participants to exchange used hypodermic needles
27 and syringes at [any exchange location, if more than one location is] available MOBILE
28 SYRINGE SERVICES SITES;
29 (3) Include appropriate levels of staff expertise in working with injecting
30 drug users and adequate staff training in providing community SERVICE PROVIDER
31 referrals, counseling, and preventive education;

HOUSE BILL 1502 3
1 (4) Provide for the dissemination of other preventive means for [curtailing
2 the spread of the HIV infection] DECREASING THE RISK OF HIV TRANSMISSION;
3 (5) Provide [a linkage for] referrals to drug counseling and treatment
4 services, and follow–up to those referrals to assure that participants receive the treatment
5 they desire;
6 (6) Educate injecting drug users on the [dangers of contracting the HIV
7 infection] RISK OF TRANSMITTING HIV or the hepatitis B virus through HIGH–RISK
8 needle–sharing practices and [unsafe] sexual behaviors;
9 (7) Include policies and procedures for the screening of applicants to the
10 Program in order to preclude noninjecting drug users from participating in the Program;
11 AND
12 (8) [Establish] IMPLEMENT procedures for identifying Program
13 participants that are consistent with the confidentiality provisions of this subtitle[; and
14 (9) Establish a method of identification and authorization for Program staff
15 members who have access to hypodermic needles, syringes, or Program records].
16 24–804.
17 (a) The Mayor of Baltimore City shall appoint an oversight committee for the
18 Program.
19 (b) The oversight committee shall consist of:
20 (1) [Two representatives] ONE REPRESENTATIVE from academia who
21 [specialize] SPECIALIZES in public health issues;
22 (2) One representative from law enforcement[, nominated by the Secretary
23 of Public Safety and Correctional Services];
24 [(3) One representative of the Baltimore City Police Department;]
25 [(4)] (3) [Two representatives] ONE REPRESENTATIVE from the
26 Maryland Department of Health[, the Department of Juvenile Services, or the Department
27 of Education, nominated by the Secretary of Health];
28 [(5)] (4) One representative of a Baltimore City community group;
29 [(6)] (5) One representative of an [AIDS] HIV advocacy group;
30 [(7)] (6) One [drug abuse] ADDICTION treatment counselor;

4 HOUSE BILL 1502
1 [(8)] (7) One recovering injecting drug user; and
2 [(9)] (8) Up to three other individuals whom the [Mayor of Baltimore
3 City] BALTIMORE CITY HEALTH DEPARTMENT determines to be appropriate for
4 appointment to the oversight committee.
5 (c) The oversight committee shall:
6 (1) Provide advice to the Commissioner of Health and the Program Director
7 on developing AND REVISING AS NECESSARY:
8 (i) Program operating procedures for the [furnishing]
9 DISTRIBUTION and exchange of hypodermic needles and syringes to injecting drug users;
10 (ii) A plan for community outreach and education;
11 (iii) A protocol for providing [a linkage] REFERRALS for Program
12 participants to [substance abuse] ADDICTION treatment and rehabilitation; and
13 (iv) A plan for evaluating the Program; and
14 (2) Provide ongoing oversight of the Program and make recommendations
15 to the Program Director or the Commissioner of Health regarding any aspect of Program
16 procedures, operation, or evaluation.
17 24–805.
18 (a) The Commissioner of Health shall appoint a Director for the Program.
19 (b) With the advice [and approval] of the oversight committee, the Director shall
20 develop AND REVISE AS NECESSARY:
21 (1) Program operating procedures for the [furnishing] DISTRIBUTION and
22 exchange of hypodermic needles and syringes to injecting drug users;
23 (2) A community outreach and education program; and
24 (3) A protocol for providing [a linkage] REFERRALS for Program
25 participants to substance abuse treatment and rehabilitation.
26 (c) The Director shall submit the operating procedures, the plan for a community
27 outreach and education program, and the [substance abuse] ADDICTION treatment
28 [linkage] REFERRAL protocol to the Commissioner of Health OR THE COMMISSIONER’S
29 DESIGNEE for approval prior to THE implementation OF REVISED PROCEDURES.

HOUSE BILL 1502 5
1 24–806.
2 (a) The Baltimore City Health Department shall include in its Program operating
3 procedures measures to collect the following data:
4 (1) The number of participants served by the Program;
5 (2) The length of time a participant is served by the Program;
6 (3) Demographic profiles of participants served by the Program that
7 include:
8 (i) Age;
9 (ii) Sex;
10 (iii) Race; AND
11 [(iv) Occupation;]
12 [(v)] (IV) Zip code of residence;
13 [(vi) Types of drugs used;
14 (vii) Length of drug use; and
15 (viii) Frequency of injection;]
16 (4) The number of hypodermic needles and syringes exchanged;
17 (5) The number of participants [entering drug counseling and] REFERRED
18 TO ADDICTION treatment; and
19 (6) The number of referrals made by the Program for [drug counseling and]
20 ADDICTION treatment FOR PEOPLE WHO INJECT DRUGS.
21 (b) With the advice [and approval] of the oversight committee, the Baltimore City
22 Health Department shall develop and implement a plan for Program evaluation that shall
23 include the following issues:
24 (1) The ESTIMATED prevalence AND INCIDENCE of HIV among Program
25 participants;
26 [(2) Changes in the level of drug use among Program participants;
27 (3) Changes in the level of needle–sharing among Program participants;

6 HOUSE BILL 1502
1 (4) Changes in the use of condoms among Program participants;
2 (5) The status of treatment and recovery for Program participants who
3 entered drug treatment programs;
4 (6) The impact of the Program on risk behaviors for the transmission of the
5 HIV infection, the hepatitis B virus, and other life–threatening blood–borne diseases
6 among injecting drug users;
7 (7) The cost–effectiveness of the Program versus the direct and indirect
8 costs of the HIV infection in terms of medical treatment and other services normally
9 required by HIV–infected individuals;]
10 [(8)] (2) The strengths and weaknesses of the Program; and
11 [(9)] (3) The advisability of continuing the Program.
12 (c) As part of its plans for data collection and Program evaluation described under
13 subsections (a) and (b) of this section, the Baltimore City Health Department shall develop
14 and implement a methodology[:
15 (1) For identifying Program hypodermic needles and syringes, such as
16 through the use of bar coding or any other method approved by the oversight committee;
17 and
18 (2) To perform HIV antibody testing on the residue left in a sample of
19 hypodermic needles and syringes returned to the Program] TO COLLECT RETURNED
20 NEEDLES AND SYRINGES AND SEND THEM TO THE RAPID ANALYSIS OF DRUGS
21 PROGRAM OPERATED BY THE CENTER FOR HARM REDUCTION AT THE MARYLAND
22 DEPARTMENT OF HEALTH.
23 (d) On or before December 31 of each year, the Baltimore City Health Department
24 shall report to the oversight committee, the Governor, and, in accordance with § 2–1257 of
25 the State Government Article, the General Assembly, on the number of hypodermic needles
26 and syringes exchanged as part of the Program.
27 24–808.
28 [(a)] No Program staff member or Program participant may be found guilty of
29 violating § 5–601, § 5–619, § 5–620, § 5–902, or § 5–904 of the Criminal Law Article for
30 possessing or distributing controlled paraphernalia or drug paraphernalia whenever the
31 possession or distribution of the controlled paraphernalia or drug paraphernalia is a direct
32 result of the employee’s or participant’s activities in connection with the work of the
33 Program authorized under this subtitle.

HOUSE BILL 1502 7
1 [(b) Notwithstanding the provisions of subsection (a) of this section, a Program
2 staff member or Program participant is not immune from criminal prosecution for:
3 (1) The redistribution of hypodermic needles or syringes in any form;
4 (2) Any activities not authorized or approved by the Program; or
5 (3) The possession or distribution of controlled paraphernalia or drug
6 paraphernalia or any other unlawful activity outside of the Baltimore City limits.]
7 24–809.
8 Except for violations of any laws that could arise from residue attached to or
9 contained within hypodermic needles or syringes being returned or already returned to the
10 Program, [nothing in] this subtitle [provides] DOES NOT PROVIDE immunity to a Program
11 staff member or Program participant from criminal prosecution for a violation of any law
12 prohibiting or regulating the use, possession, dispensing, distribution, or promotion of
13 [controlled dangerous substances, dangerous drugs, detrimental drugs, or harmful drugs
14 or any conspiracy or attempt to commit any of those offenses] ILLICIT DRUGS.
15 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
16 October 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.

[DELETED: :CA      5   C A B P F P P t b t H P S S P a t d D r t P a t m a d o t P p a g r t t A P S N a S B  A S  A  ( B  A S  A  (]
[DELETED:  H   S T A 2  ( I  ( “ AS  Sd ]HV[] Et E 2  ( T AS  Sd  E]HV[] Pt E  ( T   ( Pe f] p s ;   ( O a 2  T   ( B m lg  te[ r cf h a sf  n o h n a s i cE A A I E ECH   h   ( B a as  ;   ( I d u a a s t i p c P r]
[DELETED: H 3   ( P c tn;H     ( P a l fr r t d c a t s t   ( E d in HV HHR n ue    ( I P   ( Eh p f i P]M pe;   ( E ms 2  ( T P  ( T   ( T rs f a w]N R se    ( Ot, os;   ( O]   () T rs f t]()[] N R Mh,t oh;   () O](   () O AS ]()[]H   () O de ]()[ ]
[DELETED:  H    () O](   () U t t o i w t M o B]() Cy d t b a fBCHA I E E a  ( T   ( P o :    ( P o p f t f      ( A    ( A p f p ae f P p se     ( A   ( P t p 2  ( T  ( W al  d :   ( P fg   e   ( A   ( A p f p a le f PR p  ( T o a e p a t s ae tA]C le LO ORSET O   i .]
[DELETED: H 5 2  ( T p   ( T   ( T   ( D p o p s b t P t i    ( A    ( S    ( R    ( O]    () Z](I    ( T    ( L    ( F   ( T   ( T eOA      ( T dNF   .  ( W al  H i   ( T p   A p   ( C   ( C]
[DELETED:  H    ( C   ( T s o t a r f P p w e   ( T H i t h B v a o l b d a   ( T c o t H i i t o m t a o s n r   () T](   () T](  ( A s ay:   ( F i P h n a s s a t a   ( T p H a t o t r l i a s o h n a s r t t PT C R A S A S T T T A N O RA E A E AHRH E   ( O s t a 2  () N P s m o P p m b f g o v p p r o t e o p a i c w t w o t P]
[DELETED: H 7  ( N s   ( T   ( A   ( T p o d o c p o d p 2  E f v o a l t c a f r a t o c P nn  ps ][ s p o r t u p d d o p o c os.  S A B I F E T t A s t e O          G               ]